Skip to main content

Table 1 Epidemiological and biological features in 67 patients with HCV and cryoglobulinemia

From: Hepatitis C-related cryoglobulinemic neuropathy: potential role of oxcarbazepine for pain control

Patients (total 67) Features
Age (years) 50.4 ± 2.7
Sex ratio (M/F) 31/36
Apparent duration of disease (years) 4.1 ± 1.3
Albumin level (g/L) 39.7 ± 8.5
ALT (IU/L) 131.4 ± 16.7
Prothrombin time (%) 84.1 ± 12.2
Rheumatoid factors (n of pts. and %) 41/67 (61%)
Mean Cryoglobulinemia(g/L) 0.27 ± 0.8
Cryoglobulinemia type
 CGS TYPE II (n of pts. and %) 42/67 (64%)
 CGS TYPE III (n of pts. and %) 25/67 (36%)
 ANTI HCV Antibodies (n of pts. and %) 67/67 (100%)
 ANTI HBV Antibodies (n of pts. and %) 35/67 (52%)
 Anti HBC 30 (86%)
 HBsAg 5 (14.2)
 Anti HBS 30 (86%)
 HBeAG 0
 AntiHBe 0
 HCV RNA sequences in sera (n of pts. and %) 49/67 (73%)